RemeGen Biosciences
Zhulun Wang is an experienced leader in the biotechnology field, currently serving as the President of RemeGen Biosciences since August 2020. Prior to this role, Zhulun Wang spent over two decades at Amgen, advancing through the ranks to become Executive Director of Research, where responsibilities included heading Biologics Optimization. Additionally, Zhulun Wang held the position of Director of Research, focusing on Molecule Engineering.
RemeGen Biosciences
1 followers
RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.